文献速递炎症性肠病消化内镜

可取出支架治疗克罗恩病局灶性吻合口狭窄的单中心病例系列

Therapeutic resolution of focal, predominantly anastomotic Crohn's disease strictures using removable stents: outcomes from a single-center case series in the United Kingdom.
PubMed 文献 · Gastrointest Endosc · 2020-02-18

英国单中心病例系列评估可取出自膨胀金属支架(SEMS)治疗克罗恩病局灶性肠道狭窄的疗效与安全性。21例患者共接受23次支架治疗,多数为吻合口狭窄,随访中81%报告症状改善或缓解,88%处于临床缓解,仅5例不良事件且无穿孔、嵌顿或出血,随访期间无患者需狭窄相关手术。

要点

  • 可取出SEMS用于短段纤维性回肠/吻合口狭窄,随访中多数患者症状改善并达临床缓解
  • 不良事件少,无穿孔、嵌顿或出血等直接支架相关事件
  • 随访3-50个月内无患者需狭窄相关手术,但需头对头研究验证

核心结论

  • 可取出SEMS治疗回肠及吻合口狭窄在本系列中显示临床有效,无穿孔事件且无需狭窄相关手术值得注意。
  • 作者认为支架治疗在此背景下的疗效值得与其他狭窄解除方式开展有把握的头对头研究。

研究设计与样本

  • 英国单中心病例系列,纳入有症状的克罗恩病患者,经磁共振小肠造影评估。
  • 短(≤6 cm)纤维性回肠末端或回结肠吻合口狭窄经多学科团队评估后接受支架治疗。
  • 共21例患者、23次支架治疗,2例在随访期需重复治疗。

主要发现

  • 治疗的狭窄以吻合口为主(21处中19处),2处为原发狭窄。
  • 随访患者中81%(16例中13例)报告症状改善或缓解,88%(16例中14例)处于临床缓解。
  • 全部支架治疗中仅5例不良事件:2例支架相关不适、3例无症状支架移位。
  • 无穿孔、嵌顿或出血等直接支架相关不良事件。
  • 随访期(范围3-50个月)无患者需狭窄相关手术。

关键数值与推荐

  • 纳入标准:有症状克罗恩病,短(≤6 cm)纤维性回肠末端或回结肠吻合口狭窄。
  • 排除标准:内镜无法到达的狭窄或炎症性狭窄。
  • 所有患者使用Hanaro HRC-20-080-230部分覆膜SEMS,计划置入后7天取出。
  • 疗效采用经验证的炎症性肠病评分工具评估。

临床怎么用

  • 对经选择的短段纤维性回肠或吻合口狭窄,可考虑可取出SEMS作为避免手术的内镜治疗选择。
  • 需由多学科团队评估并排除炎症性狭窄及内镜无法到达的狭窄。
  • 计划支架置入后7天取出,并随访症状、临床缓解及支架移位等不良事件。

局限性

  • 单中心病例系列,样本量小(21例、23次支架治疗),无对照组。
  • 随访时间和评估完整性有限,部分患者未纳入随访分析。
  • 疗效需有把握的头对头研究与其他狭窄解除方式比较验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Intestinal and anastomotic strictures in Crohn's disease (CD) produce considerable morbidity. The development of surgery-sparing, endoscopic modalities for stricture resolution is essential. Removable stent therapy is emerging as an efficacious and safe means of stricture resolution. We present outcomes from the largest, single-center series of patients with CD undergoing removable self-expanding metal stent (SEMS) therapy to resolve focal intestinal strictures. METHODS: Patients with symptomatic CD were assessed with magnetic resonance enterography. Short (≤6 cm), fibrostenotic strictures of the terminal ileum or ileocolonic anastomoses were considered by a multidisciplinary team and put forward for stent therapy. Strictures were examined endoscopically and impassable strictures were treated with SEMSs. The Hanaro HRC-20-080-230 partially covered SEMS was used for all patients. Endoscopically inaccessible or inflammatory strictures were excluded. Stent retrieval was scheduled for 7 days after insertion. Therapeutic benefit was assessed with validated inflammatory bowel disease scoring tools. RESULTS: Twenty-one patients underwent 23 stent episodes, with 2 patients requiring repeat therapy in the follow-up period. Most treated strictures were anastomotic (19 of 21); 2 of 21 were de novo. Of those patients attending follow-up, 81% (13 of 16) reported symptom improvement or resolution; 88% (14 of 16) were in clinical remission at follow-up. Across all stent episodes, only 5 adverse events were noted (2 episodes of stent-related discomfort, 3 asymptomatic stent migrations). There were no direct stent-related adverse events such as perforation, impaction, or bleeding. No patient has required stricture-related surgery in the follow-up period (range, 3-50 months). CONCLUSIONS: In this series, removable SEMS therapy for ileal and anastomotic strictures was found to be clinically efficacious. The absence of perforation events and need for stricture-related surgery are noteworthy. These results suggest that the efficacy of stent therapy in this context merits powered, head-to-head investigation with other modalities for stricture resolution.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Das R, Singh R, Din S, et al. Therapeutic resolution of focal, predominantly anastomotic Crohn's disease strictures using removable stents: outcomes from a single-center case series in the United Kingdom. Gastrointest Endosc. 2020. PMID: 32081614. doi:10.1016/j.gie.2020.01.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。